- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06326606
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (Psilocybin) in Healthy Participants
MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions.
The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy adult participants.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In recent years, high-dose psilocybin has gained attention for its potential therapeutic benefits in many psychiatric indications, however existing clinical data for low psilocybin doses are limited.
Microdoses are generally considered to be those absent of profound sensory and cognitive effects that would interfere with normal everyday functioning, but only a small number of prospective studies have evaluated microdoses and/or low doses in a controlled manner.
As a foundational study of the therapeutic use of low doses of psilocybin, this study will evaluate the safety, tolerability, pharmacokinetics, and sensorial effects using a prospective, controlled, single ascending dose/multiple ascending doses in healthy volunteers.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Ken Colley, MD, PhD
- Phone Number: +1 415 225 5771
- Email: kcolley@mycomedica.com
Study Contact Backup
- Name: Marissa Lim, MD
- Phone Number: +61 3 9114 2270
- Email: marissa.lim@accelagen.com.au
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Recruiting
- CMAX Clinical Research Pty Ltd
-
Principal Investigator:
- Sepehr Shakib
-
Contact:
- Eloise Spooner
- Phone Number: +61 8 7088 7900
- Email: eloise.spooner@cmax.com.au
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Males or females aged 18 to 65 years old (inclusive) at the time of signing the informed consent form. Standard contraception measures are required for this clinical trial.
- Healthy, in the opinion of the Investigator, based on prior (history of) or current (ongoing) medical and psychiatric screening assessments.
- Participants with no clinically significant findings on physical examination, laboratory tests, and cardiac assessment.
- Body mass index (BMI) within the range 18-32 kg/m2, inclusive.
- Normal blood pressure.
- Capable of giving signed informed consent which includes the requirements and restrictions as per the approved study protocol.
Key Exclusion Criteria:
- Prior known exposure to psilocybin within the past 10 years.
- Prior (history of) or current (ongoing) diagnosis, or first-degree relatives with clinically significant medical or psychiatric condition or disease.
- History of or presence of cardiovascular disease.
- Abnormal and clinically significant ECG.
- History or presence of a neurodegenerative disorder such Alzheimer's disease or Parkinson's disease.
- Use of medications that have CNS effects or affect performance.
- Use of medications with serotonergic activity.
- History or presence of hypersensitivity or idiosyncratic reaction to psilocybin or related compounds.
- History of substance or alcohol abuse disorder in the last 1 year.
- Participant who, for any reason, is deemed by the Investigator to be inappropriate for this study; or has any condition which would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug; or is unable to comply with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: MLS101
MLS101 capsule(s) administered orally as a once a day dose
|
Capsule containing active ingredient, psilocybin
Other Names:
|
Placebo Comparator: Placebo
Active treatment matching capsules will be administered orally as a once a day dose
|
Capsule with no active ingredients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)
Time Frame: Screening (Day -60) to end of study visit (Day 8)
|
Screening (Day -60) to end of study visit (Day 8)
|
|
Occurrence of clinically significant changes in physical examination, vital signs, ECGs, clinical laboratory tests, the Columbia-Suicide Severity Rating Scale (C-SSRS).
Time Frame: Screening (Day -60) to end of study visit (Day 8)
|
The Columbia Suicide Severity Rating Scale (C-SSRS) is a short questionnaire.
If there is a positive result for suicidality on the C-SSRS after Screening (defined by a participant answering "yes" to questions 4 or 5 on the suicidal ideation portion of the C-SSRS), the participant will be evaluated by an Investigator or medically qualified Sub-investigator for continuation in the study.
Participants with suicidal ideation or behavior (a "yes" answer at any time during treatment to any one of the ten suicidal ideation and behavior questions (Categories 1-10) on the C-SSRS) at any time during the study will be withdrawn from the study.
If a participant becomes suicidal during the study, an Investigator or medically qualified Sub-investigator should provide the appropriate treatment to the participant.
|
Screening (Day -60) to end of study visit (Day 8)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of MLS101: maximum observed serum concentration (Cmax)
Time Frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
|
Pharmacokinetics of MLS10: area under the plasma concentration-time curve (AUC)
Time Frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
|
Pharmacokinetics of MLS101: time corresponding to the occurrence of Cmax (tmax)
Time Frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
|
Pharmacokinetics of MLS101: apparent terminal elimination half-life (t½)
Time Frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
|
Pharmacokinetics of MLS101: apparent total systemic clearance after oral administration (CL/F)
Time Frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
|
Pharmacokinetics of MLS101: apparent volume of distribution during the terminal phase (Vz/F)
Time Frame: Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
Day 1 to Day 3 post-dose and end of study visit (Day 8)
|
|
Sensorial effects of MLS101
Time Frame: Day 1 post-dose and end of study visit (Day 8)
|
Using validated questionnaires, the nominal sensorial threshold dose of MLS101 will be identified.
The nominal sensorial threshold dose is defined as the highest dose studied that is absent of clinically significant sensorial effects, and which would not interfere with the participant's ability to carry on with routine activities of daily living.
Higher scores indicate presence of sensorial effects.
|
Day 1 post-dose and end of study visit (Day 8)
|
Cognitive function
Time Frame: Pre-dose (Day -1), Day 1 post-dose and end of study visit (Day 8)
|
Using validated questionnaires and tools, cognitive function will be assessed and scores will be summarized for each visit, including observed values and change from baseline to evaluate the effects of MLS101 on participants' cognitive function.
|
Pre-dose (Day -1), Day 1 post-dose and end of study visit (Day 8)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sepehr Shakib, Principal Investigator at CMAX Clinical Research Pty Ltd
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-MLS101-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Psilocybin
-
University of Wisconsin, MadisonTRYP TherapeuticsWithdrawn
-
Yale UniversityHeffter Research Institute; Ceruvia Lifesciences; CH TAC LLCCompleted
-
Section for Affective Disorders; Northern Stockholm...Karolinska Institutet; Vastra Gotaland Region; Region Örebro County; Uppsala University...Recruiting
-
Yale UniversityHeffter Research InstituteActive, not recruitingMajor Depressive DisorderUnited States
-
University Health Network, TorontoCentre for Addiction and Mental HealthRecruitingDepression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant DepressionCanada
-
Yale UniversityTerminated
-
Yale UniversityCeruvia LifesciencesCompleted
-
King's College LondonUniversity of CambridgeRecruitingAutism Spectrum DisorderUnited Kingdom
-
Multidisciplinary Association for Psychedelic StudiesWithdrawnAnxiety | Stage IV MelanomaUnited States
-
University of Colorado, DenverNot yet recruitingAnhedonia | Major Depressive Disorder | Treatment Resistant DepressionUnited States